Daiichi Life Insurance Co. Ltd. Invests $1.38 Million in IQVIA Holdings Inc. $IQV

Posted by Stanley Muller on Aug 24th, 2026

Daiichi Life Insurance Co. Ltd. purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV – Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 7,115 shares of the medical research company’s stock, valued at approximately $1,375,000.

A number of other hedge funds also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its holdings in IQVIA by 244.4% during the 4th quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock worth $703,000 after acquiring an additional 2,537 shares in the last quarter. Empowered Funds LLC lifted its position in shares of IQVIA by 102.1% in the 1st quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock worth $1,715,000 after purchasing an additional 4,915 shares during the period. Sivia Capital Partners LLC purchased a new stake in shares of IQVIA in the 2nd quarter worth approximately $514,000. First Trust Advisors LP boosted its stake in shares of IQVIA by 14.8% during the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC increased its holdings in IQVIA by 5.4% during the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after buying an additional 1,155 shares during the period. 89.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have weighed in on IQV shares. Robert W. Baird upped their target price on IQVIA from $252.00 to $287.00 and gave the stock an “outperform” rating in a report on Wednesday, July 29th. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, July 15th. William Blair raised IQVIA to a “strong-buy” rating in a research report on Tuesday, July 28th. Stifel Nicolaus lifted their target price on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday, July 29th. Finally, Mizuho boosted their target price on shares of IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $241.88.

Check Out Our Latest Analysis on IQV

IQVIA Stock Performance

Shares of IQV stock opened at $260.17 on Monday. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $260.40. The business’s fifty day simple moving average is $213.32 and its 200-day simple moving average is $187.21. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. The company has a market cap of $42.82 billion, a PE ratio of 32.28, a PEG ratio of 2.21 and a beta of 1.18.

IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, topping analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a return on equity of 30.25% and a net margin of 8.10%.The firm had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same quarter last year, the firm earned $2.81 EPS. The business’s quarterly revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Analysts expect that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a stock repurchase plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to purchase up to 6.8% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its shares are undervalued.

Insider Activity at IQVIA

In other IQVIA news, insider Eric Sherbet sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The shares were sold at an average price of $249.16, for a total transaction of $1,245,800.00. Following the sale, the insider owned 20,999 shares of the company’s stock, valued at approximately $5,232,110.84. The trade was a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider W Richard Staub sold 5,500 shares of the firm’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $232.68, for a total transaction of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares of the company’s stock, valued at approximately $3,097,436.16. This represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 12,913 shares of company stock worth $3,098,793. 1.70% of the stock is owned by insiders.

IQVIA Profile

(Free Report)

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.